Technological Medical Advancements LLC marketed Diowave laser systems for unapproved uses without required FDA clearance and had serious quality-system failures.
What happened
FDA inspected the West Palm Beach, Florida facility from April 9 to April 21, 2025, and also reviewed the company's website on July 1, 2025 and product brochures and manuals. FDA found the Diowave 100 WLS and 250 WLS marketed for uses beyond the cleared indications and with different technology without required premarket approval or 510(k) clearance, making them adulterated and misbranded. The inspection also found failures in supplier and design controls, complaints, corrective actions, audits, nonconforming product control, management review, and UDI labeling.
What FDA found
Marketed the Diowave laser devices for uses beyond the cleared indications and with different technology without required premarket approval or 510(k) clearance.
FD&C Act ยงยง 501(f)(1)(B), 502(o), 515(a), 510(k), 520(g)Failed to evaluate suppliers, keep signed supplier agreements, and oversee a contract manufacturer, so key design-control records such as the design history file were missing.
21 CFR 820.50Failed to follow its complaint procedure and maintain complaint files, including investigations, failure-mode analysis, management approval, and timely review of servicing records.
21 CFR 820.198(a)Failed to establish an adequate corrective and preventive action (CAPA) procedure or open CAPAs after repeated FDA findings.
21 CFR 820.100(a)Did not conduct required quality audits in 2023, 2024, or 2025, and did not conduct a management review in 2024.
21 CFR 820.22; 21 CFR 820.20(c)Had no procedure for nonconforming product and put labels on Diowave Pure Pulse Laser System devices without the required unique device identifier (UDI).
21 CFR 820.90(a); 21 CFR 801.20(a)
What FDA wants
FDA asks the company to stop activities that cause the devices to be adulterated or misbranded, including commercial distribution for the unsupported uses, and to respond in writing within 15 business days with corrective actions, documentation, and a timetable for remaining work.
Who should pay attention
- clinics and providers using Diowave laser systems
- distributors and buyers of laser medical devices
- quality teams managing supplier, design, complaint, CAPA and UDI controls
This is a summary. Read the original letter on fda.gov.